Orthofix Medical Hits 52-Week Low at $8.85 Amid Ongoing Struggles

Orthofix Medical, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 8.85 as of June 23, 2026. This decline marks a significant downturn for the company, which has seen its stock price fluctuate considerably over the past year, with a previous high of USD 16.99. Despite the recent price drop, Orthofix has reported some positive financial metrics. The company achieved its highest operating cash flow of USD 35.17 million in March, and its raw material costs have decreased by 30.75% year-over-year. However, the stock has generated a return of -13.40% over the past year, indicating a consistent underperformance against the S&P 500 benchmark. With a market capitalization of USD 462 million, Orthofix maintains a debt-to-equity ratio of 0.17 and a price-to-book ratio of 1.03. The company currently does not offer a dividend, and its return on equity stands at -20.74%. The high institutional ownership at 100% suggests that these investors are closely monitoring the company's fundamentals, which may influence future performance.